TY - JOUR
T1 - Anti–MSP-10 IgG indicates recent exposure to Plasmodium vivax infection in the Peruvian Amazon
AU - Rosas-Aguirre, Angel
AU - Patra, Kailash P.
AU - Calderón, Maritza
AU - Torres, Katherine
AU - Gamboa, Dionicia
AU - Arocutipa, Edith
AU - Málaga, Edith
AU - Garro, Katherine
AU - Fernández, Carlos
AU - Trompeter, Grace
AU - Alnasser, Yossef
AU - Llanos-Cuentas, Alejandro
AU - Gilman, Robert H.
AU - Vinetz, Joseph M.
N1 - Funding Information:
We thank all residents and local authorities from the Loreto Villages of Cahuide and Lupuna for their enthusiastic participation in the study, as well as all field workers for their dedication during the fieldwork. We also thank Amy Bei of the Yale School of Public Health and her team and human volunteers in Senegal for the use of blood samples in this study. This study was funded by cooperative agreement U19AI089681 from the United States Public Health Service, NIH/National Institute of Allergy and Infectious Diseases, as the Amazonian International Center of Excellence in Malaria Research.
Publisher Copyright:
Copyright: © 2020, American Society for Clinical Investigation.
PY - 2020
Y1 - 2020
N2 - BACKGROUND. Serological tools for the accurate detection of recent malaria exposure are needed to guide and monitor malaria control efforts. IgG responses against Plasmodium vivax and P. falciparum merozoite surface protein-10 (MSP10) were measured as a potential way to identify recent malaria exposure in the Peruvian Amazon. METHODS. A field-based study included 470 participants in a longitudinal cohort who completed a comprehensive evaluation: light microscopy and PCR on enrollment, at least 1 monthly follow-up by light microscopy, a second PCR, and serum and dried blood spots for serological analysis at the end of the follow-up. IgG titers against novel mammalian cell–produced recombinant PvMSP10 and PfMSP10 were determined by ELISA. RESULTS. During the follow-up period, 205 participants were infected, including 171 with P. vivax, 26 with P. falciparum, 6 with infections by both species but at different times, and 2 with mixed infections. Exposure to P. vivax was more accurately identified when serological responses to PvMSP10 were obtained from serum (sensitivity, 58.1%; specificity, 81.8%; AUC: 0.76) than from dried blood spots (sensitivity, 35.2; specificity, 83.5%; AUC: 0.64) (PAUC < 0.001). Sensitivity was highest (serum, 82.9%; dried blood spot, 45.7%) with confirmed P. vivax infections occurring 7–30 days before sample collection; sensitivity decreased significantly in relation to time since last documented infection. PvMSP10 serological data did not show evidence of interspecies cross-reactivity. Anti-PfMSP10 responses poorly discriminated between P. falciparum–exposed and nonexposed individuals (AUC = 0.59; P > 0.05). CONCLUSION. Anti-PvMSP10 IgG indicates recent exposure to P. vivax at the population level in the Amazon region. Serum, not dried blood spots, should be used for such serological tests. FUNDING. Cooperative agreement U19AI089681 from the United States Public Health Service, NIH/ National Institute of Allergy and Infectious Diseases, as the Amazonian International Center of Excellence in Malaria Research.
AB - BACKGROUND. Serological tools for the accurate detection of recent malaria exposure are needed to guide and monitor malaria control efforts. IgG responses against Plasmodium vivax and P. falciparum merozoite surface protein-10 (MSP10) were measured as a potential way to identify recent malaria exposure in the Peruvian Amazon. METHODS. A field-based study included 470 participants in a longitudinal cohort who completed a comprehensive evaluation: light microscopy and PCR on enrollment, at least 1 monthly follow-up by light microscopy, a second PCR, and serum and dried blood spots for serological analysis at the end of the follow-up. IgG titers against novel mammalian cell–produced recombinant PvMSP10 and PfMSP10 were determined by ELISA. RESULTS. During the follow-up period, 205 participants were infected, including 171 with P. vivax, 26 with P. falciparum, 6 with infections by both species but at different times, and 2 with mixed infections. Exposure to P. vivax was more accurately identified when serological responses to PvMSP10 were obtained from serum (sensitivity, 58.1%; specificity, 81.8%; AUC: 0.76) than from dried blood spots (sensitivity, 35.2; specificity, 83.5%; AUC: 0.64) (PAUC < 0.001). Sensitivity was highest (serum, 82.9%; dried blood spot, 45.7%) with confirmed P. vivax infections occurring 7–30 days before sample collection; sensitivity decreased significantly in relation to time since last documented infection. PvMSP10 serological data did not show evidence of interspecies cross-reactivity. Anti-PfMSP10 responses poorly discriminated between P. falciparum–exposed and nonexposed individuals (AUC = 0.59; P > 0.05). CONCLUSION. Anti-PvMSP10 IgG indicates recent exposure to P. vivax at the population level in the Amazon region. Serum, not dried blood spots, should be used for such serological tests. FUNDING. Cooperative agreement U19AI089681 from the United States Public Health Service, NIH/ National Institute of Allergy and Infectious Diseases, as the Amazonian International Center of Excellence in Malaria Research.
UR - http://www.scopus.com/inward/record.url?scp=85079522505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079522505&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.130769
DO - 10.1172/jci.insight.130769
M3 - Article
C2 - 31770108
AN - SCOPUS:85079522505
SN - 2379-3708
VL - 5
JO - JCI insight
JF - JCI insight
IS - 1
M1 - e130769
ER -